Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Background: Bronchial asthma (asthma) is a chronic inflammatory disease of the airways, involving a variety of cells and cellular components, that manifests clinically as recurrent episodes of ...

The good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The bad is that it doesn’t seem to be any better than their already-marketed drug ...

AnaptysBio intends to assess next steps for its etokimab program after reviewing complete data from this trial, including week 16 primary endpoint data, anticipated by year-end 2020. The Company has ...

ACQ-5 scores were reduced in the asthma subset of both etokimab treatment arms vs placebo while FEV1 levels remained relatively unchanged.Additional secondary endpoint analyses were conducted upon ...

Baseline FEV1 and percent predicted FEV1 for the asthma subset in the etokimab q4w arm was 2.95 liters and 84%, 2.97 liters and 87% for the etokimab q8w arm and 3.06 liters and 87% for the placebo ...

Sixty-three percent of the etokimab q4w arm, 69% of the etokimab q8w arm and 69% of the placebo arm were diagnosed with asthma. Baseline FEV1 and percent predicted FEV1 for the asthma subset in the ...

LOS ANGELES-- (BUSINESS WIRE)--May 25, 2020-- The Law Offices of Frank R. Cruz reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on ...

On March 26, 2018, AnaptysBio revealed data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Though the Company reported improvement among ...

The Company also revealed that, as a result of this data, it had postponed the initiation of its Phase 2b etokimab clinical trial in asthma. On this news, the Company's stock price fell from $36.16 ...

On March 26, 2018, AnaptysBio revealed data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Though the Company reported improvement among ...

In the etokimab group, 73% (11 of 15 people) could eat 275 mg of peanut protein -- one nut's worth -- without an allergic reaction; no placebo recipients could do so.